Tasigna 200 mg hard capsules clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Comparative Bioavailability of Nilotinib 200 mg Hard Capsules: A Single-Dose, Open-Label, Randomized, Four-Sequence, Four-Treatment, Four-Period Crossover Pilot Study in Healthy Subjects.
This study is comparing different versions of a medicine called Nilotinib to see if they work the same way in the body. It helps us understand if new versions of medicines are as effective as existing ones, for conditions like a type of leukaemia. This is an early-stage study in healthy volunteers.
For: Primary Philadelphia-chromosome positive leukemia cells from chronic myelogenous leukemia (CML)Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II, single-arm study of de-escalation and treatment-free remission in patients with chronic myeloid leukemia treated with nilotinib in first-line therapy followed by a second attempt after nilotinib and asciminib combination: DANTE study
This study looks at stopping leukaemia medication (Tasigna, Scemblix) in two stages for people with chronic myeloid leukaemia (CML). It aims to see if patients can stay well without treatment after initial drug therapy, and what happens if they need to restart or switch medications.
For: Chronic myeloid leukemiaItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study
This study looks at new ways to treat advanced soft tissue sarcoma, a type of cancer. It uses special tests to check for changes in cancer cells and aims to find the best medicine for each person, making sure these tests are practical and quick enough.
For: Unresectable locally advanced and/or metastatic soft-tissue sarcomaFrance